Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v8-FR
Language French French
Date Updated 2021-12-07 2021-12-07
Drug Identification Number 02242971 02242971
Brand name AMIKACIN SULFATE INJECTION USP AMIKACIN SULFATE INJECTION USP
Common or Proper name AMIKACIN SO4 AMIKACIN SO4
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients AMIKACIN AMIKACIN
Strength(s) 250MG 250MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 2ML 10LIVI 2ML 10LIVI
ATC code J01GB J01GB
ATC description AMINOGLYCOSIDE ANTIBACTERIALS AMINOGLYCOSIDE ANTIBACTERIALS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2021-10-25 2021-10-25
Estimated end date 2021-12-10 2021-12-10
Actual end date 2021-12-06 2021-12-06
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments
Health Canada comments